Immunologist Leender Trouw specialises in the complement system, which is part of the immune system. In some diseases drugs help activate or inhibit this system. This is best done ‘in the right place at the right time’ − the title of his inaugural lecture.

A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…

Since the invasion of Ukraine in 2022, Russia has been conducting a covert sabotage campaign against Europe. The ‘Bewaken en Beveiligen’ (Surveillance and Security) project team at Leiden University has investigated the scale of these operations and compiled its findings in the report Russian Operations…

Conference

In dermatology, there should be a high level of multidisciplinary collaboration among institutes and specialists, Professor of Translational Dermatology, Robert Rissmann, will say in his inaugural lecture on 8 July. He is building an infrastructure that will put pre-clinical and clinical skin research…

Two Leiden researchers have been awarded ERC Proof of Concept grants. These grants, each worth EUR 150,000, will help the grantees in their efforts to bridge the gap from basic science to real-life applications

PhD defence

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

With a €1.5 million European grant, industrial ecologist Stefano Cucurachi will work on more sustainable production methods for the pharmaceutical industry. The Italian company Angelini Pharma intends to use the resulting knowledge to make its production process more sustainable.

One in two people will be diagnosed with cancer. World Cancer Day on 4 February raises awareness of the impact of this devastating disease. Leiden University is conducting various studies aimed at preventing and controlling cancer. Below are just a few examples.

‘’ And then the world changed forever ,welcome to the future’’. These are the words that Kausik Ray (President of the European Atherosclerosis Society) spoke when the worldwide first dose of inclisiran, a novel SiRNA based cholesterol lowering agent, was administered at the Cardiology lipid clinic at…

Leiden researchers, led by Sebastian Pomplun developed a new method to screen hundreds of thousands of molecules for drug discovery, using mass spectrometry instead of DNA tags. ‘We wanted to make drug discovery faster and more accessible.’

Four university medical centres, including the LUMC, are joining forces to increase pandemic preparedness in the Netherlands.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.

Book Presentation | Studium Generale Lecture

If you’d like to record videos or podcasts yourself or use our studios, you can read more here about the available facilities and how to easily loan the necessary equipment or plan studio recordings.

Lecture, Hybrid workshop

Grotius Dialogue

Chronic pain, nausea or vomiting due to chemotherapy. If you suffer from such ailments, medicinal cannabis can be a godsend. Though a downside is that it can make patients high. Therefore, Leiden researchers from the Oncode Institute are investigating alternatives that do not make you high. In Nature…

PhD defence

Weblectures are lectures that recorded on campus and made available online afterwards. The instructor can choose between a livestream or a weblecture.

Here you will find an overview of the course offerings for FGGA lecturers.

Digital tools and campus facilities for active learning and digital assessment.

Here you will find information about the (digital) tools available to you as a teacher, along with the support offered by FLO. You will also find information about several practical matters related to teaching at our faculty, such as registering grades.

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

Leiden researcher Anne-Grete Märtson brought together a large number of studies to better understand antibiotic dosing in patients with obesity. The publication in a renowned medical journal has already garnered much positive reactions, Märtson says. ‘It’s high time researchers started sharing more…

A web lecture is a lecture that’s recorded on campus and available online. You can decide for yourself whether to offer the lecture via a livestream and/or make it available for later viewing.

A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.

For each university unit, the ICT Shared Service Centre (ISSC) has an appointed ICT contact person responsible for applying for ICT facilities for research, teaching and operational management.

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’

PhD defence

PhD defence

The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What’s more, the bacterium is far less likely to return, a major issue with existing antibiotics. The research was published in Nature Communications.

A new class of polymers has been used in patients for the first time. The compound is the first new drug solubilising agent in decades. Introduced in 2014 by chemist Matthias Barz from Leiden University, it offers a unique alternative to current options.